(4-fluorobutyl)triphenylphosphonium bromide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-fluorobutyl)triphenylphosphonium bromide
• 英文别名: 4-Fluorobutyltriphenylphosphonium bromide；4-fluorobutyl(triphenyl)phosphanium;bromide
• 化学式: Br*C₂₂H₂₃FP
• 分子量: 417.301
• InChiKey: BCFFRHCBTADGMJ-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  1.73
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (4-fluorobutyl)triphenylphosphonium bromide 、 间硝基苯甲醛 以 甲苯 为溶剂， 以43.885%的产率得到
  参考文献：
  名称：

  Synthesis of fluorinated analogues of sphingosine-1-phosphate antagonists as potential radiotracers for molecular imaging using positron emission tomography

  摘要：

  Sphingosine-1-phosphate (S1P) receptors play major roles in cardiovascular, immunological and neurological diseases. The recent approval of the sphingolipid drug Fingolimod (Gilenya®), a sphingosine-1-phosphate agonist for relapsing multiple sclerosis, in 2010 exemplifies the potential for targeting sphingolipids for the treatment of human disorders. Moreover, non-invasive in vivo imaging of S1P receptors that are not available till now would contribute to the understanding of their role in specific pathologies and is therefore of preclinical interest. Based on fluorinated analogues of the S1P1 receptor antagonist W146 showing practically equal in vitro potency as the lead structure, the first S1P receptor antagonist [18F]-radiotracer has been synthesized and tested for in vivo imaging of the S1P1 receptor using positron emission tomography (PET). Though the tracer is serum stable, initial in vivo images show fast metabolism and subsequent accumulation of free [18F]fluoride in the bones.

  DOI：

  10.1016/j.bmc.2014.08.009
• 作为产物：
  描述：

  1-溴-4-氟丁烷 、 三苯基膦 以 甲苯 为溶剂， 以86%的产率得到(4-fluorobutyl)triphenylphosphonium bromide
  参考文献：
  名称：

  Synthesis of fluorinated analogues of sphingosine-1-phosphate antagonists as potential radiotracers for molecular imaging using positron emission tomography

  摘要：

  Sphingosine-1-phosphate (S1P) receptors play major roles in cardiovascular, immunological and neurological diseases. The recent approval of the sphingolipid drug Fingolimod (Gilenya®), a sphingosine-1-phosphate agonist for relapsing multiple sclerosis, in 2010 exemplifies the potential for targeting sphingolipids for the treatment of human disorders. Moreover, non-invasive in vivo imaging of S1P receptors that are not available till now would contribute to the understanding of their role in specific pathologies and is therefore of preclinical interest. Based on fluorinated analogues of the S1P1 receptor antagonist W146 showing practically equal in vitro potency as the lead structure, the first S1P receptor antagonist [18F]-radiotracer has been synthesized and tested for in vivo imaging of the S1P1 receptor using positron emission tomography (PET). Though the tracer is serum stable, initial in vivo images show fast metabolism and subsequent accumulation of free [18F]fluoride in the bones.

  DOI：

  10.1016/j.bmc.2014.08.009

文献信息

• Fluoroalkylated liquid-crystal compounds, liquid-crystal compositions, and liquid-crystal display elements
  申请人：Chisso Corporation

  公开号：US06254941B1

  公开（公告）日：2001-07-03

  The present invention provides liquid crystalline compounds having a very high voltage holding ratio, very little variation of these properties depending on temperature, high &Dgr;n, and good compatibility in the other liquid crystal materials particularly under a low temperature, liquid crystal compositions containing these crystalline compounds, and liquid crystal display devices constituted by using the liquid crystal compositions. The liquid crystalline compounds are represented by general formula (1): wherein R represents an alkyl, alkoxy or alkoxyalkyl group of 2-20 carbon atoms, and in each group, any 1-3 hydrogen atoms may be replaced by fluorine atoms; X shows an halogen atom or an alkyl group of 1-20 carbon atoms, any methylene groups (—CH2—) not adjacent each other in the alkyl group may be replaced by oxygen atoms, and any one or more hydrogen atoms in the alkyl group may be replaced by fluorine atoms; Z1, Z2 and Z3, each independently, represents —(CH2)2—, —(CH2)4—, —CH2O—, —OCH2—, —(CH2)3O—, —O(CH2)3— or a covalent bond; Y1-Y16 each independently represent hydrogen atoms or fluorine atoms, but at least two represent fluorine atoms; m represents 0 or 1, and any atom constituting the compound may be replaced by an isotope thereof.

  本发明提供了具有非常高的电压保持比、在不同温度下性质变化非常小、高&Dgr;n和在其他液晶材料中具有良好相容性（特别是在低温下）的液晶化合物、含有这些晶体化合物的液晶组合物，以及使用液晶组合物构成的液晶显示装置。液晶化合物由通式（1）表示：其中R表示2-20碳原子的烷基、烷氧基或烷氧基烷基，并且在每个基团中，任意1-3个氢原子可以被氟原子替换；X表示卤素原子或1-20碳原子的烷基，烷基中不相邻的任何亚甲基（—CH2—）可以被氧原子替换，并且烷基中的任意一个或多个氢原子可以被氟原子替换；Z1、Z2和Z3分别独立地表示—(CH2)2—、—(CH2)4—、—CH2O—、—OCH2—、—(CH2)3O—、—O(CH2)3—或共价键；Y1-Y16各自独立地表示氢原子或氟原子，但至少有两个表示氟原子；m表示0或1，化合物中的任何原子都可以被其同位素替换。
• N-substituted phenylacetamide derivative and pharmaceutical composition containing the same
  申请人：Morie Toshiya

  公开号：US20090082463A1

  公开（公告）日：2009-03-26

  The invention provides the following compound (I): wherein R 1 is methoxy group, hydroxyl group or hydrogen atom; R 2 is hydrogen atom, C 1-4 alkyl group, C 1-4 alkylcarbonyl group or arylcarbonyl group; D is a group of the following formula (A), (B), or (C). The compound is useful as a medicament for treating neuropathic pain or pain caused by various diseases such as rheumatoid arthritis and osteoarthritis, and inflammation.

  本发明提供以下化合物（I）：其中，R1是甲氧基、羟基或氢原子；R2是氢原子、C1-4烷基、C1-4烷基羰基或芳基羰基；D是下式（A）、（B）或（C）的基团。该化合物可用作治疗神经病理性疼痛或由风湿性关节炎和骨关节炎等各种疾病引起的疼痛和炎症的药物。
• N-substituted phenylacetamide derivative and pharmaceutical composition containing the same
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：US07767854B2

  公开（公告）日：2010-08-03

  The invention provides the following compound (I): wherein R1 is methoxy group, hydroxyl group or hydrogen atom; R2 is hydrogen atom, C1-4 alkyl group, C1-4 alkylcarbonyl group or arylcarbonyl group; D is a group of the following formula (A), (B), or (C). The compound is useful as a medicament for treating neuropathic pain or pain caused by various diseases such as rheumatoid arthritis and osteoarthritis, and inflammation.

  本发明提供以下化合物(I)：其中R1是甲氧基、羟基或氢原子；R2是氢原子、C1-4烷基、C1-4烷基羰基或芳基羰基；D是以下公式(A)、(B)或(C)的基团。该化合物可用作治疗神经病性疼痛或由类风湿性关节炎和骨关节炎等各种疾病引起的疼痛和炎症的药物。
• FLUOROALKENYL DERIVATIVES AND LIQUID CRYSTAL COMPOSITIONS
  申请人：CHISSO CORPORATION

  公开号：EP0884296A1

  公开（公告）日：1998-12-16

  The present invention is to provide liquid crystalline compounds having a wide temperature range of a liquid crystal phase, low viscosity, and large ratio of elastic constants; liquid crystal compositions comprising the compound; and liquid crystal display devices comprising the composition; the liquid crystalline compounds being fluoroalkenyl derivatives expressed by the general formula (1) wherein A1, A2, A3, and A4 independently represent trans-1,4-cyclohexylene group or 1,4-phenylene group; Z1, Z2, and Z3 independently represent -(CH2)2-, -CH=CH-, -C≡C-, or a covalent bond; Q represents H or F; ℓ is an integer of 1 to 5; m, n, and o are independently an integer of 0 to 5; p and q are independently an integer of 0 or 1; and each element which constitutes the derivatives may be an isotope of the element.

  本发明旨在提供具有宽温度范围液晶相、低粘度和大弹性常数比的液晶化合物；包含该化合物的液晶组合物；以及包含该组合物的液晶显示设备；该液晶化合物为通式(1)表示的氟烯烃衍生物 其中 A1、A2、A3 和 A4 独立地代表反式-1,4-环己烯基团或 1,4-亚苯基基团；Z1、Z2 和 Z3 独立地代表-(CH2)2-、-CH=CH-、-C≡C- 或共价键；Q 代表 H 或 F；ℓ 是 1 至 5 的整数；m、n 和 o 独立地是 0 至 5 的整数；p 和 q 独立地是 0 或 1 的整数；构成衍生物的每个元素可以是该元素的同位素。
• N-SUBSTITUTED PHENYLACETAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP1884510A1

  公开（公告）日：2008-02-06

  The invention provides the following compound (I): wherein R1 is methoxy group, hydroxyl group or hydrogen atom; R2 is hydrogen atom, C1-4 alkyl group, C1-4 alkylcarbonyl group or arylcarbonyl group; D is a group of the following formula (A), (B), or (C). The compound is useful as a medicament for treating neuropathic pain or pain caused by various diseases such as rheumatoid arthritis and osteoarthritis, and inflammation.

  本发明提供了以下化合物 (I)： 其中 R1 是甲氧基、羟基或氢原子；R2 是氢原子、C1-4 烷基、C1-4 烷基羰基或芳基羰基；D 是下式（A）、（B）或（C）的基团。 该化合物可用作治疗神经性疼痛或各种疾病（如类风湿性关节炎和骨关节炎）和炎症引起的疼痛的药物。